Akira Nakagawara
Overview
Explore the profile of Akira Nakagawara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
204
Citations
6547
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yoneda A, Shichino H, Hishiki T, Matsumoto K, Ohira M, Kamijo T, et al.
Pediatr Blood Cancer
. 2024 Apr;
71(6):e30976.
PMID: 38577760
Purpose: Survival rates of patients with high-risk neuroblastoma are unacceptable. A time-intensified treatment strategy with delayed local treatment to control systemic diseases has been developed in Japan. We conducted a...
2.
Li C, Kurkure P, Arora R, Chen B, Kirgizov K, Okamoto Y, et al.
JCO Glob Oncol
. 2023 Sep;
9:e2300153.
PMID: 37656946
In Asia, a few countries have a long and established history of collaborative clinical trials successfully formed national children's cancer study groups, but many still do not have such groups....
3.
Izumi H, Kaneko Y, Nakagawara A
Cells
. 2023 Mar;
12(5).
PMID: 36899954
CD133, also called prominin-1, is widely known as a cancer stem cell marker, and its high expression correlates with a poor prognosis in many cancers. CD133 was originally discovered as...
4.
Ando K, Nakagawara A
Cells
. 2023 Feb;
12(4).
PMID: 36831211
The Runt-related transcription factor (RUNX) family, which is essential for the differentiation of cells of neural crest origin, also plays a potential role in neuroblastoma tumorigenesis. Consecutive studies in various...
5.
Izumi H, Li Y, Yasunami M, Sato S, Mae T, Kaneko Y, et al.
Stem Cells
. 2022 Mar;
40(4):371-384.
PMID: 35284915
CD133 is a transmembrane protein that mainly localizes to the plasma membrane in hematopoietic/neural stem cells and cancer stem cells. Although CD133 also localizes to the cytoplasm and is degraded...
6.
Major A, Palese M, Ermis E, James A, Villarroel M, Klussmann F, et al.
JCO Glob Oncol
. 2022 Feb;
8:e2100266.
PMID: 35157510
Purpose: The global pediatric oncology clinical research landscape, particularly in Central and South America, Africa, and Asia, which bear the highest burden of global childhood cancer cases, is less characterized...
7.
Hara J, Nitani C, Shichino H, Kuroda T, Hishiki T, Soejima T, et al.
Jpn J Clin Oncol
. 2022 Feb;
52(5):486-492.
PMID: 35137156
Background: In Japan, allogeneic hematopoietic stem cell transplantation is widely performed for recurrent neuroblastomas. This retrospective study aimed to investigate the prognosis of recurrent neuroblastoma in Japan and explore the...
8.
Ohira M, Nakamura Y, Takimoto T, Nakazawa A, Hishiki T, Matsumoto K, et al.
Biomolecules
. 2022 Jan;
12(1).
PMID: 35053166
Neuroblastomas (NBs) exhibit broad and divergent clinical behaviors and tumor risk classification at diagnosis is crucial for the selection of an appropriate therapeutic strategy for each patient. The present study...
9.
Kumamoto T, Yamazaki F, Nakano Y, Tamura C, Tashiro S, Hattori H, et al.
Int J Clin Oncol
. 2021 Dec;
27(1):262-263.
PMID: 34859328
No abstract available.
10.
Kumamoto T, Yamazaki F, Nakano Y, Tamura C, Tashiro S, Hattori H, et al.
Int J Clin Oncol
. 2021 Oct;
26(12):2161-2178.
PMID: 34633580
Li-Fraumeni syndrome (LFS) is a hereditary tumor that exhibits autosomal dominant inheritance. LFS develops in individuals with a pathogenic germline variant of the cancer-suppressor gene, TP53 (individuals with TP53 pathogenic...